Search

Search results

35 results found

Prolonged clonazepam-induced withdrawal symptoms in an NAT2 ultraslow acetylator. Pharmacogenomics, 20(2), 69–73. https://doi.org/10.2217/pgs-2018-0145

Publication: Journal Article

“Prolonged Clonazepam-Induced Withdrawal Symptoms in an NAT2 Ultraslow Acetylator. Pharmacogenomics, 20(2), 69–73. Https://Doi.org/10.2217/Pgs-2018-0145”. 2019. Journal of Iaculis Nisl Facilisis Malesuada Maecenas.

Results from a 78-week, single-arm, open-label phase 2 study to evaluate UX007 in pediatric and adult patients with severe long-chain fatty acid oxidation disorders (LC-FAOD). Journal of inherited metabolic disease, 42(1), 169–177.

Publication: Journal Article

“Results from a 78-Week, Single-Arm, Open-Label Phase 2 Study to Evaluate UX007 in Pediatric and Adult Patients With Severe Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD). Journal of Inherited Metabolic Disease, 42(1), 169–177.”. 2019. Journal of Inherited Metabolic Disease.

Mission

Page

A Phase 3 Multi-Center Study to Evaluate the Safety and Efficacy of Subcutaneous Injections of Pegvaliase in Adolescent Subjects (Ages 12-17) with Phenylketonuria Featuring an Open-Label Randomized Two-Arm (Active vs Diet-Only Control) Design/BMN 165-306

News: June 05, 2020

A Phase 3 Multi-Center Study to Evaluate the Safety and Efficacy of Subcutaneous Injections of Pegvaliase in Adolescent Subjects (Ages 12-17) with Phenylketonuria Featuring an Open-Label Randomized Two-Arm (Active vs. Diet-Only Control) Design ClinicalTrials.gov ID NCT05270837 Sponsor BioMarin...